{"id":45850,"date":"2025-11-05T11:24:37","date_gmt":"2025-11-05T03:24:37","guid":{"rendered":"https:\/\/flcube.com\/?p=45850"},"modified":"2025-11-05T11:25:47","modified_gmt":"2025-11-05T03:25:47","slug":"metsera-faces-escalating-bidding-war-as-novo-nordisks-10-b-offer-tops-pfizers-revised-proposal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45850","title":{"rendered":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal"},"content":{"rendered":"\n<p>Biotech\u2011focused <strong>Metsera<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MTSR:NASDAQ\">NASDAQ: MTSR<\/a>) announced that <strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) has submitted a <strong>\u201csuperior\u201d<\/strong> acquisition proposal that outstrips <strong>Pfizer\u2019s<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-terms-at-a-glance\">Deal Terms at a Glance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Acquirer<\/th><th>Share Price (USD)<\/th><th>Implied Value (USD)<\/th><th>Premium to Sep\u201119 Close*<\/th><\/tr><\/thead><tbody><tr><td><strong>Novo\u202fNordisk<\/strong><\/td><td><strong>$86.20<\/strong> (up to)<\/td><td><strong>\u2248\u202f$10\u202fbillion<\/strong><\/td><td><strong>\u2248\u202f159\u202f%<\/strong><\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td><strong>$70.00<\/strong> (up to)<\/td><td><strong>\u2248\u202f$8.1\u202fbillion<\/strong><\/td><td>\u2014 (revised from original $4.9\u2011$7.3\u202fbillion range)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*September\u202f19 was the last trading day before Pfizer first announced its intent to acquire Metsera.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novo\u202fNordisk\u2019s offer<\/strong> includes an upfront cash component plus contingent earn\u2011outs tied to regulatory milestones for Metsera\u2019s pipeline.<\/li>\n\n\n\n<li><strong>Pfizer\u2019s revised proposal<\/strong> shortens its original $4.9\u202fbillion cash deal (potentially $7.3\u202fbillion with milestones) to a flat $8.1\u202fbillion valuation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-legal-battle-timeline\">Legal Battle Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Event<\/th><\/tr><\/thead><tbody><tr><td><strong>Oct\u202f31,\u202f2025<\/strong><\/td><td>Pfizer files a <strong>breach\u2011of\u2011contract<\/strong> suit against Metsera, alleging fiduciary\u2011duty violations and tortious interference.<\/td><\/tr><tr><td><strong>Nov\u202f3,\u202f2025<\/strong><\/td><td>Pfizer initiates a <strong>second lawsuit<\/strong> targeting Novo\u202fNordisk and Metsera, claiming the bid breaches antitrust law.<\/td><\/tr><tr><td><strong>Nov\u202f4,\u202f2025<\/strong><\/td><td>Delaware judge <strong>denies<\/strong> Pfizer\u2019s request for an immediate restraining order; a hearing is rescheduled for later that day.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Under the original merger agreement, Pfizer has a <strong>four\u2011business\u2011day negotiation window<\/strong> to amend its offer. If Metsera\u2019s board deems Novo\u202fNordisk\u2019s proposal superior after this window, the company may <strong>terminate<\/strong> the Pfizer merger agreement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metsera-s-pipeline-why-the-fight\">Metsera\u2019s Pipeline \u2013 Why the Fight?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral &amp; Injectable GLP\u20111 Candidate<\/strong> \u2013 Designed for <strong>once\u2011monthly<\/strong> dosing, aiming to improve adherence versus weekly injectables.<\/li>\n\n\n\n<li><strong>Amylin\u2011Targeting Molecule<\/strong> \u2013 Also positioned for <strong>monthly administration<\/strong>, potentially addressing both glucose control and weight management.<\/li>\n<\/ul>\n\n\n\n<p>Both assets are early\u2011stage but represent a <strong>strategic entry<\/strong> into the fast\u2011growing obesity\u2011treatment market, a segment where:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pfizer<\/strong> has struggled to bring its own obesity drugs to market.<\/li>\n\n\n\n<li><strong>Novo\u202fNordisk<\/strong> faces <strong>share\u2011price pressure<\/strong> from competitors such as <strong>Eli\u202fLilly<\/strong> and lower\u2011cost biosimilars.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-analyst-outlook\">Market Impact &amp; Analyst Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation Gap:<\/strong> The <strong>$1.9\u202fbillion<\/strong> premium Novo\u202fNordisk offers over Pfizer signals strong confidence in the commercial potential of Metsera\u2019s monthly candidates.<\/li>\n\n\n\n<li><strong>Share Reaction:<\/strong> Metsera\u2019s stock surged <strong>\u2248\u202f17\u202f%<\/strong> on the news, while Pfizer fell <strong>\u2248\u202f4\u202f%<\/strong> and Novo\u202fNordisk slipped <strong>\u2248\u202f2\u202f%<\/strong> on the heightened uncertainty.<\/li>\n\n\n\n<li><strong>Regulatory Risk:<\/strong> The antitrust suit could delay or block the transaction, extending the timeline for any potential synergies.<\/li>\n\n\n\n<li><strong>Strategic Fit:<\/strong> If completed, Novo\u202fNordisk would solidify its dominance in the GLP\u20111 space, while Pfizer would gain a foothold in the emerging <strong>once\u2011monthly<\/strong> obesity segment.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the proposed transactions, legal proceedings, and market expectations. Actual results may differ materially due to risks including regulatory approvals, litigation outcomes, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45852,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4364,4365,148,860,863,86,309],"class_list":["post-45850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-metsera","tag-nasdaq-mtsr","tag-novo-nordisk","tag-nyse-nvo","tag-nyse-pfe","tag-obesity","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition proposal that outstrips Pfizer\u2019s (NYSE: PFE) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45850\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal\" \/>\n<meta property=\"og:description\" content=\"Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition proposal that outstrips Pfizer\u2019s (NYSE: PFE) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45850\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T03:24:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T03:25:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal\",\"datePublished\":\"2025-11-05T03:24:37+00:00\",\"dateModified\":\"2025-11-05T03:25:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0501.webp\",\"keywords\":[\"Metsera\",\"NASDAQ: MTSR\",\"Novo Nordisk\",\"NYSE: NVO\",\"NYSE: PFE\",\"Obesity\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45850#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45850\",\"name\":\"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0501.webp\",\"datePublished\":\"2025-11-05T03:24:37+00:00\",\"dateModified\":\"2025-11-05T03:25:47+00:00\",\"description\":\"Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition proposal that outstrips Pfizer\u2019s (NYSE: PFE) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45850\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45850#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal - Insight, China&#039;s Pharmaceutical Industry","description":"Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition proposal that outstrips Pfizer\u2019s (NYSE: PFE) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45850","og_locale":"en_US","og_type":"article","og_title":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal","og_description":"Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition proposal that outstrips Pfizer\u2019s (NYSE: PFE) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.","og_url":"https:\/\/flcube.com\/?p=45850","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T03:24:37+00:00","article_modified_time":"2025-11-05T03:25:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45850#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45850"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal","datePublished":"2025-11-05T03:24:37+00:00","dateModified":"2025-11-05T03:25:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45850"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45850#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp","keywords":["Metsera","NASDAQ: MTSR","Novo Nordisk","NYSE: NVO","NYSE: PFE","Obesity","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45850#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45850","url":"https:\/\/flcube.com\/?p=45850","name":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45850#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45850#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp","datePublished":"2025-11-05T03:24:37+00:00","dateModified":"2025-11-05T03:25:47+00:00","description":"Biotech\u2011focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a \u201csuperior\u201d acquisition proposal that outstrips Pfizer\u2019s (NYSE: PFE) latest counter\u2011offer. The development intensifies a high\u2011profile corporate showdown that has already generated two lawsuits and a pending antitrust challenge.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45850#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45850"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45850#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp","width":1080,"height":608,"caption":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45850#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Metsera Faces Escalating Bidding War as Novo\u202fNordisk\u2019s $10\u202fB Offer Tops Pfizer\u2019s Revised Proposal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45850"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45850\/revisions"}],"predecessor-version":[{"id":45855,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45850\/revisions\/45855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45852"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}